Establishing a Platform for Personalized Approach to the Management of Rectal Adenocarcinoma Using Patient-Derived Tumoroids and Organoids


About this study

The purpose of this study is to create a database of rectal cancer cells that can be studied outside of the patient's body.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years of age.
  • Have an ECOG Performance Status of ≤ 2.
  • No evidence of distant metastasis on imaging.
  • Histologic or cytologic proven adenocarcinoma of the rectum.
  • Providing informed consent prior to enrollment in the trial.

Exclusion Criteria: 

  • Inability to obtain additional core needle biopsies for generating PDTOs.
  • Patients who received colorectal cancer chemotherapy or pelvic radiation in the past 5 years.
  • Females who are pregnant or plan to become pregnant.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Jeremy Jones, M.D.

Open for enrollment

Contact information:

Monique Jones

(904) 953-1348

More information


Publications are currently not available

Mayo Clinic Footer